BSc MBBS PhD (Lond), DIC, MRCP (UK), FHEA, FIDSA, FRCPCH, MA, FMedSci
Professor of Paediatric Infection and Immunity
Current research activities include clinical trials of new and improved vaccines for children and adults, surveillance of invasive bacterial diseases and penumococcal vaccine impact in children in Nepal, studies of cellular and humoral immune responses to glycoconjugate and typhoid vaccines, and development of a serogroup B meningococcal vaccine.
ANDREW J POLLARD, FRCPCH PhD FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford, Director of the Oxford Vaccine Group, Fellow of St Cross College and Honorary Consultant Paediatrician at the Children’s Hospital, Oxford, UK. He obtained his medical degree at St Bartholomew’s Hospital Medical School, University of London in 1989 and trained in Paediatrics at Birmingham Children’s Hospital, UK, specialising in Paediatric Infectious Diseases at St Mary’s Hospital, London, UK and at British Columbia Children’s Hospital, Vancouver, Canada. He obtained his PhD at St Mary’s Hospital, London, UK in 1999 studying immunity to Neisseria meningitidis in children and proceeded to work on anti-bacterial innate immune responses in children in Canada before returning to his current position at the University of Oxford, UK in 2001. He received the Bill Marshall award of the European Society for Paediatric Infectious Disease (ESPID) in 2013 for his contribution to the specialty and the ESPID Distinguished Award for Education & Communication in 2015.
He chaired the UK’s National Institute for Health and Care Excellence (NICE) meningitis guidelines development group, and the NICE topic expert group developing quality standards for management of meningitis and meningococcal septicaemia. He chairs the UK Department of Health’s Joint Committee on Vaccination and Immunisation and the European Medicines Agency scientific advisory group on vaccines and is a member of WHO’s SAGE. His research includes the design, development and clinical evaluation of vaccines including those for meningococcal disease and enteric fever and leads studies using a human challenge model of (para)typhoid. He has a particular interest in the development of B cell immunity in early childhood. He runs surveillance for invasive bacterial diseases and studies the impact of pneumococcal vaccines in children in Nepal and leads a project on burden and transmission of typhoid in Nepal, Bangladesh and Malawi. He has supervised 23 PhD students and his publications include over 300 manuscripts and books on various topics in paediatrics and infectious diseases.
Publisher Correction: Clonal analysis of Salmonella-specific effector T cells reveals serovar-specific and cross-reactive T cell responses.
Napolitani G. et al, (2019), Nature immunology
Logistics of Implementing a Large-scale Typhoid Vaccine Trial in Kathmandu, Nepal.
Colin-Jones R. et al, (2019), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 68, S138 - S145
Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial.
Theiss-Nyland K. et al, (2019), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 68, S67 - S73
Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIIb Trial.
Theiss-Nyland K. et al, (2019), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 68, S74 - S82
Accelerating Typhoid Conjugate Vaccine Introduction: What Can Be Learned From Prior New Vaccine Introduction Initiatives?
Jamka LP. et al, (2019), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 68, S171 - S176